Satoru Kuroda
Technik-/Wissenschafts-/F&E-Leiter bei Aphoenix, Inc.
Profil
Satoru Kuroda is currently the Chief Technology Officer at Aphoenix, Inc. Prior to this, he worked as a Principal at Astellas Pharma, Inc. He received his undergraduate degree in 1986 and his doctorate degree in 1999 from Kyushu University.
Aktive Positionen von Satoru Kuroda
| Unternehmen | Position | Beginn |
|---|---|---|
Aphoenix, Inc.
 Aphoenix, Inc. Medical/Nursing ServicesHealth Services Aphoenix, Inc. is a holding company that operates as a chemical genomics firm. It specializes in the affinity purification technology using special nano-scale beads and other supporting technologies, such as medicinal chemistry, mass spectroscopy, informatics and molecular, biology. The firm exploits drugs, which lack known mechanisms of action as probes for discovering druggable targets, and then develop such compounds against validated targets. The company was founded in 2002 and is headquartered in Tokyo, Japan . | Technik-/Wissenschafts-/F&E-Leiter | 27.04.2009 |
Ehemalige bekannte Positionen von Satoru Kuroda
| Unternehmen | Position | Ende |
|---|---|---|
| ASTELLAS PHARMA INC. | Corporate Officer/Principal | - |
Ausbildung von Satoru Kuroda
| Kyushu University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ASTELLAS PHARMA INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Aphoenix, Inc.
Aphoenix, Inc. Medical/Nursing ServicesHealth Services Aphoenix, Inc. is a holding company that operates as a chemical genomics firm. It specializes in the affinity purification technology using special nano-scale beads and other supporting technologies, such as medicinal chemistry, mass spectroscopy, informatics and molecular, biology. The firm exploits drugs, which lack known mechanisms of action as probes for discovering druggable targets, and then develop such compounds against validated targets. The company was founded in 2002 and is headquartered in Tokyo, Japan . | Health Services |
